Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.

Christoffer Rosén; Bahman Farahmand; Tobias Skillbäck; Katarina Nägga; Niklas Mattsson; Lena Kilander; Dorota Religa; Anders Wimo; Kaj Blennow; Bengt Winblad; Henrik Zetterberg; Maria Eriksdotter

doi:10.1016/j.jalz.2015.04.007

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.

Christoffer Rosén, Bahman Farahmand, Tobias Skillbäck, Katarina Nägga, Niklas Mattsson, Lena Kilander, Dorota Religa, Anders Wimo, Kaj Blennow, Bengt Winblad, Henrik Zetterberg, Maria Eriksdotter

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Sammanfattning

New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.

Originalspråk	engelska
Sidor (från-till)	1470-1479
Tidskrift	Alzheimer's & Dementia
Volym	11
Nummer	12
DOI	https://doi.org/10.1016/j.jalz.2015.04.007
Status	Published - 2015

Ämnesklassifikation (UKÄ)

Neurologi

Tillgång till dokument

10.1016/j.jalz.2015.04.007

http://www.ncbi.nlm.nih.gov/pubmed/26079415?dopt=Abstract

Citera det här

Rosén, C., Farahmand, B., Skillbäck, T., Nägga, K., Mattsson, N., Kilander, L., Religa, D., Wimo, A., Blennow, K., Winblad, B., Zetterberg, H., & Eriksdotter, M. (2015). Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer's & Dementia, 11(12), 1470-1479. https://doi.org/10.1016/j.jalz.2015.04.007

@article{5d2ad5bed4a2429b8dcba7bffc3210d9,

title = "Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.",

abstract = "New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.",

author = "Christoffer Ros{\'e}n and Bahman Farahmand and Tobias Skillb{\"a}ck and Katarina N{\"a}gga and Niklas Mattsson and Lena Kilander and Dorota Religa and Anders Wimo and Kaj Blennow and Bengt Winblad and Henrik Zetterberg and Maria Eriksdotter",

year = "2015",

doi = "10.1016/j.jalz.2015.04.007",

language = "English",

volume = "11",

pages = "1470--1479",

journal = "Alzheimer's & Dementia",

issn = "1552-5279",

publisher = "Wiley",

number = "12",

}

Rosén, C, Farahmand, B, Skillbäck, T, Nägga, K, Mattsson, N, Kilander, L, Religa, D, Wimo, A, Blennow, K, Winblad, B, Zetterberg, H & Eriksdotter, M 2015, 'Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.', Alzheimer's & Dementia, vol. 11, nr. 12, s. 1470-1479. https://doi.org/10.1016/j.jalz.2015.04.007

TY - JOUR

T1 - Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.

AU - Rosén, Christoffer

AU - Farahmand, Bahman

AU - Skillbäck, Tobias

AU - Nägga, Katarina

AU - Mattsson, Niklas

AU - Kilander, Lena

AU - Religa, Dorota

AU - Wimo, Anders

AU - Blennow, Kaj

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Eriksdotter, Maria

PY - 2015

Y1 - 2015

N2 - New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.

AB - New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.

U2 - 10.1016/j.jalz.2015.04.007

DO - 10.1016/j.jalz.2015.04.007

M3 - Article

C2 - 26079415

SN - 1552-5279

VL - 11

SP - 1470

EP - 1479

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 12

ER -

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.

Sammanfattning

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Fingeravtryck

Citera det här